^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    daunorubicin

    i
    Other names: FI-6339, RP-13057
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor, DNA intercalator
    Related drugs:
    3d
    A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=70, Suspended, St. Jude Children's Research Hospital | Recruiting --> Suspended
    Trial suspension
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV
    5d
    Phenazine 5,10-dioxide analogues as potential therapeutics in AML: Efficacy on patient-derived blasts, in zebrafish larvae xenografts and synergy with venetoclax. (PubMed, Transl Oncol)
    The phenazine 5,10-dioxides cytotoxicity towards primary blasts correlated with the blast's sensitivity to daunorubicin, presumably due to similar mode of action towards AML cells. Additionally, synergism with the AML drug venetoclax (VTX) was found in the AML cell lines MOLM-13 and MV4-11. The efficacy of phenazine 5,10-dioxides towards primary AML blasts, synergism with VTX and low toxicity in effective concentrations in zebrafish larva AML xenografts suggests potential for these compounds in future AML therapy for patients unfit for intensive chemotherapy.
    Journal
    |
    CD34 (CD34 molecule)
    |
    Venclexta (venetoclax) • daunorubicin
    7d
    Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients (clinicaltrials.gov)
    P2, N=20, Terminated, Institute of Hematology & Blood Diseases Hospital, China | N=40 --> 20 | Recruiting --> Terminated; The research center has conducted a more comprehensive study.
    Enrollment change • Trial termination • Minimal residual disease
    |
    NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • NUP214 (Nucleoporin 214) • DEK (DEK Proto-Oncogene)
    |
    NPM1 mutation
    |
    Venclexta (venetoclax) • azacitidine • daunorubicin
    11d
    A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2/3, N=80, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P2/3 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • BL-M11D1
    14d
    CHARACTERISTIC OF MYELOID SARCOMA BY CANCER GENOME PROFILING AND ALGORITHM OF POTENTIAL BIOMARKERS FOR UTERINE MESENCHYMAL TUMOR. (PubMed, Georgian Med News)
    In cancer treatment, contrast-enhanced MRI is useful for identifying the size and location of tumor masses. However, contrast-enhanced MRI does not lead to the diagnosis of tumor masses. Therefore, early blood tests and tumor biopsy results are important for differential diagnosis and early treatment decisions.
    Journal
    |
    IL2 (Interleukin 2)
    |
    daunorubicin
    16d
    Tirabrutinib-anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance. (PubMed, Expert Opin Drug Metab Toxicol)
    Our in vitro data demonstrate that tirabrutinib influences daunorubicin pharmacodynamics by targeting both metabolic and transport pathways. However, Chou - Talalay analysis highlights the importance of appropriate dosing to achieve therapeutic synergy in combination regimens.
    Journal
    |
    AKR1C3 (Aldo-Keto Reductase Family 1 Member C3)
    |
    daunorubicin • Velexbru (tirabrutinib)
    19d
    Investigating of harmane, harmine, and norharman as inhibitors of MDR1 and MRP1 to overcome chemotherapy resistance in cancer cells. (PubMed, Sci Rep)
    In conclusion, these alkaloids enhanced the sensitivity of EPG85.257RDB and A2780 cells to daunorubicin, likely through inhibition of drug efflux activity. These findings highlight β-carboline alkaloids as promising candidates for combination therapy in overcoming multidrug resistance in cancer.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    daunorubicin
    24d
    AML-DS-2025: The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia (clinicaltrials.gov)
    P3, N=100, Recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology
    New P3 trial
    |
    GATA1 (GATA Binding Protein 1)
    |
    cytarabine • etoposide IV • daunorubicin • idarubicin hydrochloride
    25d
    Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML (clinicaltrials.gov)
    P2, N=240, Recruiting, Guangdong Provincial People's Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • daunorubicin • idarubicin hydrochloride • mitoxantrone
    28d
    Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=102, Not yet recruiting, OHSU Knight Cancer Institute
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • daunorubicin • idarubicin hydrochloride • fludarabine IV • Starasid (cytarabine ocfosfate)
    28d
    P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Jul 2026
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • daunorubicin
    29d
    CircRAD18 Regulates Daunorubicin Resistance in Acute Myeloid Leukemia Cells through MiR-185-5p/HDGF Axis (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    Knocking down CircRAD18 can reduce HDGF expression by up-regulating miR-185-5p, thereby weakening DNR resistance in AML cells, inhibiting KG1a cell proliferation under DNR treatment, and promoting apoptosis.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • PCNA (Proliferating cell nuclear antigen) • miR-185 (MicroRNA 185) • HDGF (Heparin Binding Growth Factor)
    |
    daunorubicin